---
schema_version: "secwatch.filing_event.v1"
accession: "0001802768-23-000005"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2023-02-15T23:59:59+00:00"
generated_at: "2026-06-19T11:51:39.183745+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Royalty Pharma Q4 Adj Cash Receipts up 96% YoY; guides FY23 $2.375-$2.475B excl. $475M milestone

## Summary
- Q4 2022 Adj Cash Receipts $1,064M (+96% YoY); FY 2022 $2,789M (+31%).
- Q4 GAAP operating cash flow $570M (+16% YoY); FY $2,144M (+6%).
- Announced transactions up to $3.5B in 2022, including $2.0B in upfront payments.
- FY 2023 guidance: Adj Cash Receipts $2,375M-$2,475M, underlying growth 4-9% prior to Biohaven payments; excludes potential $475M zavegepant milestone.
- In 2023, agreed to provide $500M upfront to Ionis Pharmaceuticals for a new partnership.

## SEC filing metadata
- accession: 0001802768-23-000005
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2023-02-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000180276823000005/0001802768-23-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000180276823000005/rprx-20230215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001802768-23-000005
- JSON: https://secwatch.observer/filing/0001802768-23-000005.json
- Plain text: https://secwatch.observer/filing/0001802768-23-000005.txt

## Key facts
- Earnings Releases
  Royalty Pharma plc updated its the quarter and year ended December 31, 2022 guidance (initiated).
  - Period: the quarter and year ended December 31, 2022
  - Guidance: initiated
  - Result: reported results
  source text: On February 15, 2023, Royalty Pharma plc issued a press release announcing its financial results for the quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802768/000180276823000005/0001802768-23-000005-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.